Background. Retrospective studies of haemodialysis patients from large dialysis organizations in the United States have indicated that intravenous vitamin D may be associated with a survival benefit. However, patients prescribed vitamin D are generally healthier than those who are not, suggesting that treatment by indication may have biased previous findings. Additionally, no survival benefit associated with vitamin D has been shown in a recent metaanalysis in CKD patients. Because treatment-by-indication bias due to both measured and unmeasured confounders cannot be completely accounted for in standard regression or marginal structural models (MSMs), this study evaluates the association between vitamin D and mortality among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS) using standard regression and MSMs with an expanded set of covariates, as well as by instrumental variable models to minimize potential bias due to unmeasured confounders. Methods. Data from 38 066 DOPPS participants from 12 countries between 1996 and 2007 were analysed. Mortality risk was assessed using standard baseline and timevarying Cox regression models, adjusted for demographics and detailed comorbidities, and MSMs. In models similar to instrumental variable analysis, the facility percentage of patients prescribed vitamin D, adjusted for the patient case mix, was used to predict patient-level mortality. Results. Vitamin D prescription was significantly higher in the USA compared to other countries. On average, patients prescribed vitamin D had fewer comorbidities compared to those who were not. Vitamin D therapy was associated Conclusions. Vitamin D was associated with a survival benefit in models prone to bias due to unmeasured confounding. In agreement with a meta-analysis of randomized controlled studies, no difference in mortality was observed in instrumental variable models that tend to be more independent of unmeasured confounding. These findings indicate that a randomized controlled trial of vitamin D and clinical outcomes in haemodialysis patients are needed and can be ethically conducted.
Introduction
In a recent guideline document, Kidney Disease: Improving Global Outcomes (KDIGO) defines chronic kidney disease-mineral and bone disorder (CKD-MBD) as a systemic syndrome characterized by abnormalities in serum calcium, phosphorus and parathyroid hormone (PTH) concentrations, in vitamin D metabolism, and in bone turnover that may be associated with soft tissue calcification [1] . This syndrome is common among CKD patients and has been associated with an increased risk for cardiovascular 964 F. Tentori et al. calcifications [2] [3] [4] , arterial dysfunction [5, 6] , morbidity and mortality [7, 8] . The standard of care suggested by the 2003 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines included targeted therapy with dietary phosphorus restriction, phosphorus binders and administration of vitamin D analogues [9] .
Non-mineral effects of vitamin D therapy have been described, including effects on the immune and inflammatory system [10, 11] , effects on the renin-angiotensin system [12] , apoptosis [13] and cellular proliferation [14] and differentiation [15] . These biological actions are generally beneficial and may contribute to the improved survival reported for non-CKD patients with malignancies and sepsis who receive vitamin D analogues [16, 17] . Observational studies have reported a survival benefit for end-stage renal disease (ESRD) patients on maintenance haemodialysis (HD) who received vitamin D analogues [18] [19] [20] [21] [22] . A study of Japanese patients receiving oral vitamin D demonstrated a decreased risk for cardiovascular but not for all-cause mortality [18] . In a retrospective analysis of patients starting HD at facilities operated by Fresenius Medical Care North America, Teng et al. reported a 20% survival advantage for patients receiving intravenous (IV) vitamin D versus those who did not [19] . Similar results were subsequently reported in analyses of administrative databases from other large dialysis organizations in the USA [20, 21] . Given the suggestion of the beneficial biological effects of vitamin D, nephrologists may be tempted to consider vitamin D as a panacea for HD patients and extend its prescription beyond current clinical practice guidelines. However, no large clinical outcomes trial has been performed, and a recent metaanalysis of clinical trials in patients with CKD concluded that beneficial effects of vitamin D on patient-level outcomes are unproven [23] . The different results reported by observational studies may be explained by the fact that-in the absence of randomization-patients prescribed vitamin D tended to be overall healthier compared to those not on vitamin D. It is possible that model adjustments failed to fully account for treatment-by-indication bias, and therefore the reported survival benefit may be due to underlying health status rather than treatment with vitamin D. Specifically, the role of unmeasured confounders that could not be accounted for in model adjustments may have led to biased results.
This study explores the relationship between vitamin D therapy and mortality in the international Dialysis Outcomes and Practice Patterns Study (DOPPS) [24, 25] . In addition to standard regression and marginal structural model analyses, to address treatment-by-indication bias and specifically the effect of unmeasured confounding factors, we also applied an instrumental variable approach that used the percentage of patients prescribed vitamin D at each facility as the predictor [26] [27] [28] .
Methods
The DOPPS design has been previously described [24, 25] . The current study analysed data from a representative sample of 38 066 HD patients in 12 countries that participated in the three phases of the DOPPS. In DOPPS I (1996-2001), 8609 patients were randomly sampled from 308 dialysis facilities in France, Germany, Italy, Japan, Spain, the UK and the USA. The prevalent cross-section in DOPPS II (2002) (2003) (2004) and DOPPS III (2005-present) included 9103 and 7757 patients randomly sampled from 322 and 295 facilities, respectively, from the original seven countries, plus Australia, Belgium, Canada, New Zealand and Sweden. Institutional review boards in each country approved the study, and informed consent was obtained in accordance with local requirements.
Patient data were obtained by medical record abstraction. Data regarding demographic factors, comorbid conditions, laboratory values, type of vascular access and prescription of IV and oral vitamin D analogues (collectively referred to as 'vitamin D') were collected upon study entry. Longitudinal data, including laboratory measurements and vitamin D prescription, were collected at 4-month intervals.
Statistical methods
Standard descriptive statistics described prevalent crosssections of participants. In DOPPS I, II, and III, the adjusted odds of a patient being prescribed vitamin D at enrolment given his/her demographic and clinical characteristics were assessed in multivariable regression analyses. Multivariable discrete-time Poisson regression models were utilized to identify factors associated with vitamin D initiation among patients not prescribed vitamin D at baseline (n = 16 456), and with vitamin D cessation among patients prescribed vitamin D at baseline (n = 14 785).
The relationship between vitamin D prescription and mortality was assessed using five different modelling approaches. First, baseline standard regression models assessed the association between vitamin D prescription (yes/no) at the time of enrolment and risk of death over the course of follow-up.
Longitudinal data were collected in DOPPS every 4 months. Time-varying standard regression was used to assess the association between mortality risk in a 4-month interval and vitamin D prescription (yes/no) in the last week of the prior 4-month interval. Patients were allowed to switch both into and out of the vitamin D treatment category. Separate sets of models were created based on route of vitamin D administration (IV versus oral). Since results were not meaningfully different, we only reported results combining any vitamin D versus none. Standard regression models were run both unadjusted and adjusted for expanding sets of patient characteristics including baseline demographics and dialysis dose (age, sex, race, years with ESRD, diabetes, single pool Kt/V and year of enrolment in DOPPS), comorbid conditions [diabetes mellitus, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, other cardiovascular disease, hypertension, lung disease, cancer, GI bleeding, neurologic disease, psychological disorders, prior parathyroidectomy, cellulitis/gangrene, HIV/AIDS and vascular access type (AV fistula, graft or catheter)] and either baseline or time-varying laboratory values from the same 4-month interval as the vitamin D prescription (serum albumin, haemoglobin, calcium, phosphorus, PTH and dialysate calcium). In order to account for confounding without inappropriately adjusting for intermediate variables between vitamin D dosing and outcomes [29] , baseline and time-varying marginal structural models (MSMs) were constructed. MSMs used patient vitamin D prescription to predict mortality risk over the course of the study (baseline) or in the subsequent 4-month interval (time-varying models), with time-at-risk beginning at Month 4. In the MSMs, Cox models were weighted using each patient's inverse probability of vitamin D treatment at study entry (for baseline MSMs) and at the start of each 4-month interval (for timevarying MSMs), given each patient's baseline case mix, comorbid conditions, laboratory values in the current and prior intervals, vitamin D prescription in the prior interval, DOPPS study phase and region (North America = US + Canada; Europe/ANZ = European countries + Australia and New Zealand; and Japan) using a logistic regression model. Using this approach, each patient's weight was standardized by his/her adjusted probability of vitamin D prescription, given his/her baseline case mix, comorbidities and the vitamin D prescription in the prior interval [30] .
Standard regression and MSMs cannot overcome bias due to unmeasured confounding. In order to address bias in vitamin D prescription due to unmeasured confounders [31] , the association between vitamin D and mortality was assessed in models similar to instrumental variable models in assumptions and construction to the grouped treatment variable approach [32] . A facility's propensity to prescribe vitamin D was modelled as the adjusted proportion of patients on vitamin D at a facility, estimated by linear mixed regression with vitamin D as the outcome and all case-mix, comorbid and baseline laboratory factors as predictor variables with facility treated as a random effect. The intercept for the random effect was considered the expected level of treatment at each facility, or the percentage of patients at a facility who were prescribed vitamin D and were adjusted for the facility case mix and other measured factors that could influence the prescription of vitamin D. Thus, the adjusted facility percentage of vitamin D use, which was applied to each patient at the corresponding facility, was not influenced by an individual patient's characteristics, which could have influenced their mortality risk. The instrumental variables used as predictors of patient mortality were: (a.) a facility being in the highest versus lowest quartile of facility percentage of vitamin D use and, (b.) the adjusted percentage of patients at a facility receiving vitamin D. The facility-level predictors were applied to all patients at that facility and used to predict each patient's mortality risk in unadjusted and adjusted Cox models.
Sensitivity analyses used baseline standard regression models to compare the relationship between mortality risk and IV versus oral vitamin D compounds among all patients, and between mortality risk and the most commonly prescribed oral (alphacalcidol, calcitoriol and other) and IV (calcitriol, paricalcitol, doxercalciferol and maxacalcitol) vitamin D compounds among DOPPS III patients (where information was available on the types of oral vitamin D analogues). In a second sensitivity analysis, time-varying vitamin D prescription was redefined to include patients with a prescription for vitamin D at study entry to remain in the treated category, while those with no prescription for vitamin D at baseline were allowed to switch into the treated category at the start of the first interval when he/she was prescribed vitamin D [19] . An additional sensitivity analysis restricted baseline, standard regression models to patients with similar levels of serum calcium (< and ≥10 mg/dl), phosphorus (< and ≥5.5 mg/dl) and PTH (< and ≥150 pg/ml) at study entry.
All Cox models accounted for facility clustering effects using robust standard error estimation techniques and were stratified by the study phase and geographic region of the DOPPS to account for differences in the availability of vitamin D analogues and survival rates across different countries over time. Patients were considered to be at risk from study enrolment until the date of death (within 60 days of departure from a facility), loss to follow-up, or study end. Results were expressed as relative rates/ratios (RR) with corresponding 95% confidence intervals (CI). P-values <0.05 were considered statistically significant.
Statistical analyses were performed with SAS software, version 9.1 (SAS Institute; Cary, NC, USA).
Results

International patterns of vitamin D prescription
The practice of vitamin D prescription over time and the route of administration varied widely among countries ( Figure 1 ). Vitamin D was prescribed for 54% of participants in the cross-sectional sample of DOPPS III. The percentage of patients on vitamin D ranged from 33% in France to 66% in the USA. With the exception of an 8% increase in vitamin D prescription from DOPPS II to DOPPS III in the USA, the percentage of patients on vitamin D remained stable over the follow-up time in all countries. While the IV route was largely preferred in the USA (62% of patients), in all other countries oral administration was more common (34-67% of patients). Among patients on IV vitamin D, the most commonly prescribed compounds were calcitriol (66.8%), paricalcitol (25.9%) and doxercalciferol (2.4%).
Distributions of the percentage of patients at each facility prescribed vitamin D by country and DOPPS phase are shown in Figure 2 . Similar to the patient-level findings, the practice of facility vitamin D prescription in the USA tended to increase over time. No significant differences in prescription patterns were observed over time in other DOPPS countries. versus 26.8%), was significantly lower among patients on vitamin D. Concentrations of serum albumin, calcium, phosphorus and PTH were higher in patients prescribed vitamin D (P < 0.001). Similar to the findings across all DOPPS countries, within each region patients on vitamin D were also younger and had fewer comorbid conditions than those not prescribed vitamin D (data not shown).
Characteristics of patients prescribed vitamin D
Predictors of initiation and cessation of vitamin D use (Table 2)
Participants in any DOPPS country were less likely to be started on vitamin D compared to participants in the USA (P < 0.0001). Factors significantlyassociated with vitamin D initiation were black race, time on dialysis <1 year or >6 years, low haemoglobin, low serum calcium and high PTH. Cessation of vitamin D was more likely for patients outside of the USA, of any race other than black, with <1 year on dialysis, having had a prior parathyroidectomy, with lower haemoglobin, serum albumin, or PTH, and with higher serum calcium, phosphorus or dialysate calcium.
Patient characteristics at facilities with vitamin D prescription below or above the regional median (Table 3)
Overall, patients in facilities where vitamin D prescription was above the regional median (48% in Europe/ANZ, 59% in Japan and 54% in North America) did not appear to have characteristics associated with better or worse health compared to patients in facilities with below-median vitamin D prescription. Although the distribution of patient characteristics was not entirely balanced, no systematic differences were evident, indicating that the facility pattern of vitamin D prescription tended to be independent of the facility case mix.
Mortality risk associated with vitamin D prescription (Table 4)
The median follow-up time was . When testing the association between specific vitamin D analogues and mortality in facility-level models, no survival differences were found between facility percentage prescription of calcitriol, paricalcitol or doxercalciferol. Among DOPPS III patients, no significant differences were found between the association of mortality risk and different types of oral vitamin D analogues (data not shown). Additionally, there were no significant differences in the association between vitamin D and mortality in baseline, standard regression models restricted to patients with similar levels of serum calcium (< and ≥10 mg/dl), phosphorus (< and ≥5.5 mg/dl) and PTH (< and ≥150 pg/ml).
Discussion
Patients prescribed vitamin D had longer survival, but were also younger and had case mix and laboratory characteristics that are generally associated with greater longevity than patients not prescribed vitamin D (Table 1 ). The observed RRs for survival in standard regression models and MSMs were remarkably similar to those previously reported [19] [20] [21] . However, results from instrumental variable approach models suggest that previous studies may have failed to account for unmeasured patient confounders. As in prior studies [19] [20] [21] , our study found significant differences in measured case-mix characteristics between patients prescribed vitamin D and those who were not. Our results confirm that higher serum albumin concentrations in patients prescribed vitamin D [20] strongly suggest an overall healthier status. With the addition of a comprehensive list of patient demographics, comorbidities and laboratory covariate adjustments, the survival benefit virtually disappeared in baseline models and was substantially attenuated in timevarying models. These results suggest that associations of vitamin D prescription with improved survival are, in part, due to health status and that biologic effects of vitamin D analogues may be non-significant or small. With MSMs it is possible to adjust for confounding effects of time-varying variables that may be both confounders and intermediate variables, such as serum calcium, phosphorus or PTH levels [29] . This technique has been used in dialysis patient studies to assess associations of vitamin D [19] , and iron with mortality [33] , and associations of ESA dosing with haemoglobin levels [34] . The 16% and 22% reduction in mortality risk observed in our unadjusted baseline and time-varying MSMs, respectively, are smaller than the 27% reduction reported by Teng et al. [19] . Substantially, greater levels of comorbidity adjustments in our models may partially explain the smaller magnitude. However, it is essential to note that MSMs can only address the effect of measured confounders, but not unmeasured ones. Despite many covariates, it is likely that unmeasured or unknown confounders remain unaccounted for in both standard regression and MSMs analyses.
In our analyses, no difference in survival was found between facilities with higher or lower vitamin D prescription when using an instrumental variable approach. This technique was developed to reduce treatment selection bias and offers the particular advantage of accounting for unmeasured confounders [26, 27, 31] . This same technique was recently used to estimate relationships between several treatments and clinical outcomes [27, 28, 35] . In our instrumental variable models, the adjusted facility percentage vitamin D prescription, which is reflective of a facility's likelihood to prescribe vitamin D based on clinical practice preferences and not the case mix of patients at that facility, was used to predict mortality instead of the patient's individual vitamin D prescription, which might be determined by the patient characteristics that could also be associated with altered mortality risk. To this point, demographic distributions, comorbidities and laboratory values were substantially more comparable in facilities with vitamin D prescription above and below the median (Table 3 ) than in comparisons of patients treated versus not treated with vitamin D (Table 1) . This indicates that differences in case mix were accounted for by this facility-practice-based approach. Nonetheless, this approach also adjusts for the same variables at the patient level and considers the facility's propensity to use vitamin D based on its case mix.
The lack of association between vitamin D therapy and improved survival in our facility-level models concurs with a recent meta-analysis of a randomized controlled trial of vitamin D in CKD that concluded that 'beneficial effects on patient-level outcomes (including death, hospitalization, cardiovascular events or fractures) of vitamin D are unproven' [23, 36] . However, due to the small number of patients included in mortality trials and the methodological limitations of meta-analyses, no definite conclusion should be drawn from these results.
In the current study, no survival advantage was found for newer IV vitamin D analogues (i.e. paricalcitol and doxercalciferol) versus calcitriol. Since the results of other observational studies are controversial [20, 37] and no randomized controlled trials on this topic are available, the Results of our facility-level models are not subject to the bias found in some ecological studies, which are based on aggregates of patients and do not adjust for patientlevel characteristics [38] . To avoid the limitations of the ecological design, we analysed outcomes with adjustment for patient characteristics at the patient level while using a facility-level treatment variable (the facility percentage of patients on vitamin D) to further reduce bias that could arise from unmeasured covariates. This approach reduces treatment-by-indication bias while also accounting fully for observed confounders at the individual level [39] .
In contrast with other observational studies [19, 20] , our study population represents a cross-sectional sample of patients at participating facilities. This approach enables us to address the clinically important question of the relationship of vitamin D therapy to outcomes among patients across patient-years on dialysis. Since the DOPPS sample is representative of the worldwide HD population [40] , these results are applicable to the practice of nephrology in a variety of countries across the world.
We acknowledge that the current study is susceptible to several limitations inherent to the observational design of DOPPS. Specifically, despite the comprehensive adjustments and the use of an instrumental variable approach, the possibility still remains that some sources of bias may have not been taken into account.
Due to the limited data available, we were unable to account for several aspects of vitamin D dosing that may affect patient outcomes, including vitamin D exposure prior to study entry and vitamin D dose. We also acknowledge the possibility that lack of compliance for patients prescribed an oral vitamin D analogue could bias our results. However, this is unlikely because in analyses restricted to patients who received oral versus IV vitamin D, no difference in mortality was found by route of administration.
The international nature of the DOPPS enabled us to describe differences and document substantial variations in vitamin D prescription patterns in 12 countries over a decade. Percentages of patients at each facility prescribed vitamin D tended to increase from DOPPS I to DOPPS III in the USA but not in other DOPPS regions (Figure 1 ). Increased vitamin D prescription in the USA may be related to published studies and the renewed interest in vitamin D, particularly in the US nephrology community [19] [20] [21] . Most patient characteristics associated with initiation of vitamin D therapy were inversely associated with cessation of vitamin D therapy, and vice-versa (Table 3 ). The duration of dialysis <1 year before study enrolment (versus 3-5 years) and low haemoglobin (<9.6 versus 10.8-11.8 g/dl) levels were significantly associated with both initiation and cessation of vitamin D. These associations point to the complexities of patient characteristics and provider preferences that influence decisions to prescribe vitamin D in the international HD community.
The established infrastructure and the collaborative support of the DOPPS investigators represent major strengths of the current study. The international design allowed us to assess relationships between vitamin D and mortality across HD patient populations, taking advantage of substantial variations in practice patterns that occur due to provider preferences rather than case mix alone. Finally, the large collection of DOPPS information allowed us to adjust models for many potentially confounding covariates, including 14 major classes of comorbid conditions based on ∼70 comorbidity indicators [25] .
In conclusion, this study raises questions about the previously reported survival advantage associated with vitamin D therapy. Although unadjusted models agree with prior reports, this advantage was attenuated or lost with more detailed adjustment for patient characteristics. Further analyses based on each facility's practice of vitamin D prescription as an instrumental variable to minimize potential treatment-by-indication bias show no survival benefit associated with vitamin D. These findings indicate that results of prior observational studies should be interpreted with caution and offer a different perspective to the ongoing debate regarding the survival benefits of vitamin D therapy. More importantly, our results indicate that it is ethical to conduct a much-needed clinical trial to clarify the impact of vitamin D on mortality among patients undergoing maintenance HD.
